Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could just 5 radiation sessions be as good as 15 for breast cancer?

NCT ID NCT03677427

Disease control Sponsor: University Hospital, Ghent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests whether an accelerated radiation schedule of 5 sessions over 10-12 days works as well as the standard 15-session schedule for women who have had breast-conserving surgery for breast cancer. The study measures breast shape changes two years after treatment. If the shorter schedule proves effective, it could mean fewer hospital visits and potentially fewer side effects for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy in 5 sessions versus 15 sessions
What this could lead to
If successful, a 5-session radiation schedule could become a standard option, reducing treatment burden and improving quality of life for many breast cancer patients.
What could go wrong
This is a single randomized trial; results may not apply to all patients. The shorter schedule might have different long-term side effects or tumor control rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

488 people

The number who actually took part.

Started

Oct 2017

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * female patients with non-metastatic breast cancer, * age ≥ 18 years, * breast conserving surgery, * multidisciplinary decision of adjuvant breast irradiation, * informed consent obtained, signed and dated before specific protocol procedures Exclusion Criteria: * distant metastases, * bilateral breast irradiation, * history of previous radiation treatment to the same region * life expectancy of less than 2 years, * planned reconstructive surgery, * conditions making toxicity evaluation difficult (e.g. skin disorders), * patients unlikely to comply with the protocol (e.g. inability to return for follow-up visits or unlikely to complete the study).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Radiotherapie UZ Gent

    Ghent, Oost-Vlaanderen, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.